

Review

Natural Products and Nutrients against Different Viral Diseases: Prospects in Prevention and Treatment of SARS-CoV-2

Syed Ghazanfar Ali ^{1,*}, Mohammad Azam Ansari ², Mohammad A. Alzohairy ³, Ahmad Almatroudi ³, Mohammad N. Alomary ^{4,*}, Saad Alghamdi ⁵, Suriya Rehman ² and Haris M. Khan ¹

¹ Viral Research Diagnostic Laboratory, Department of Microbiology, Jawaharlal Nehru Medical College A.M.U., Aligarh U.P.202002, India; harismk2003@hotmail.com

² Department of Epidemic Disease Research, Institutes for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia; maansari@iau.edu.sa (M.A.A.); surrehman@iau.edu.sa (S.R.)

³ Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Qassim 51431, Saudi Arabia; dr.alzohairy@gmail.com (M.A.A.); aamtrody@qu.edu.sa (A.A.)

⁴ National Centre for Biotechnology, King Abdulaziz City for Science and Technology (KACST), P.O. Box 6086, Riyadh 11442, Saudi Arabia

⁵ Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah21955, Saudi Arabia; ssalghamdi@uqu.edu.sa

* Correspondence: syedmicro72@gmail.com (S.G.A.); malomary@kacst.edu.sa (M.N.A.)

Citation: Ali, S.G.; Ansari, M.A.; Alzohairy, M.A.; Almatroudi, A.; Alomary, M.N.; Alghamdi, S.; Rehman, S.; and Khan, H.M. Natural Products and Nutrients against Different Viral Diseases: Prospects in Prevention and Treatment of SARS-CoV-2. *Medicina* **2021**, *57*, 169. <https://doi.org/10.3390/medicina57020169>

Academic Editors: Robert H. Schneider and Mahadevan Seetharaman

Received: 7 January 2021

Accepted: 7 February 2021

Published: 14 February 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

Abstract: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a global pandemic and is posing a serious challenge to mankind. As per the current scenario, there is an urgent need for antiviral that could act as a protective and therapeutic against SARS-CoV-2. Previous studies have shown that SARS-CoV-2 is much similar to the SARS-CoV bat that occurred in 2002-03. Since it is a zoonotic virus, the exact source is still unknown, but it is believed bats may be the primary reservoir of SARS-CoV-2 through which it has been transferred to humans. In this review, we have tried to summarize some of the approaches that could be effective against SARS-CoV-2. Firstly, plants or plant-based products have been effective against different viral diseases, and secondly, plants or plant-based natural products have the minimum adverse effect. We have also highlighted a few vitamins and minerals that could be beneficial against SARS-CoV-2.

Keywords: antiviral; medicinal plants; pandemic; SARS-CoV-2; zoonotic virus

1. Introduction

Coronaviruses under the realm of Riboviria belongs to the order Nidovirales, sub-order cornidovirinea, family Coronaviridae [1]. Orthocoronavirinae the subfamily of coronaviridae is further divided into four genera alpha (a), beta (b), gamma (c), and delta (d) coronavirus. Further, SARS-CoV belongs to Beta coronavirus and sarbecovirus is the subgenus of SARS-CoV-2 [2]. It shares similar homology with bat coronavirus and it has been estimated that both have 96.2% sequence homology [3].

The two epidemics due to coronavirus have already occurred that were due to SARS-CoV and the Middle East respiratory syndrome (MERS) and both have been the major cause of pneumonia in humans [4]. SARS-CoV emerged in 2002 and remained till 2003 during the period it caused 774 death and more than 800 people were infected. MERS-CoV emerged in Saudi Arabia in 2012, which caused more than 800 deaths, and 2500 people became infected [5].

Coronaviruses have single-stranded RNA as genetic material that can range from 26

kbs to 32 kbs in length. Coronaviruses possess specific genes in Open Reading Frame ORF1 downstream region that are responsible for encoding the proteins responsible for viral replication, nucleocapsid, and spike formation [6]. The structure of SARS-CoV shows the spikes on the outer surface. Furthermore, studies have shown that structural proteins are encoded by the four structural genes, which include spike (S), envelope (E), membrane (M), and nucleocapsid (N) gene. These genes are responsible for viral functionality and structure [7].

SARS-CoV-2 genome is 80% similar to the previous human coronavirus SARS-CoV [8]. For some of the encoded proteins such as coronavirus main proteinase (3CLpro), papain-like protease (PLpro), and RNA-dependent RNA polymerase (RdRp) the sequence similarity is very high (96%) between SARS-CoV, and SARS-CoV-2 [9].

SARS-CoV-2 and SARS-CoV spike protein have 76.5% identical amino acid sequences [10]. The 3D structures of spike proteins of SARS-CoV-2 and SARS-CoV as analyzed by computer imaging revealed that both have identical structures in the receptor-binding domain and maintains the Vander Waals force [10]. The major amino acid residue of SARS-CoV-2 in the receptor-binding domain is Gln-493, which favors the attachment of spike protein S with human cells more specifically with the lungs therefore the attachment results in respiratory infections in humans [11,12]. Zhao et al. [11] have suggested that 83% of the angiotensin-converting enzyme (ACE-2) expressing cells are alveolar epithelial type II, therefore, these cells can be the reservoir for the viral invasion. Some analysts have suggested that SARS-CoV-2 binds to ACE-2 more efficiently as compared with SARS-CoV, therefore, it has a greater ability to transmit from person to person [13].

Initially, for the attachment to the host cells, virus use the spike (S) glycoprotein, which also mediates the host and viral cell membrane fusion during infection [14]. The spike (S) glycoprotein has two regions namely S1 and S2. S1 helps in the binding of host cell receptors, and S2 helps in the fusion with the membrane. The receptor-binding domain (RBD) is located in the S1 region of SARS-CoV and the attachment of the human host cell with the virus is mediated by the RBD protein of the RBD domain with the angiotensin-converting enzyme (ACE-2) as a receptor similar to the one required by SARS-CoV [15,16]. Since SARS-CoV and SARS-CoV-2 are much similar, it is believed that SARS-CoV-2 uses a similar receptor (ACE-2) for entering into human host cells [10,13].

The initial clinical symptoms that appear after SARS-CoV-2 infection are pneumonia, fever, dry cough, headache dyspnea, and in acute cases leads to respiratory failure and eventually, death occurs [17–19]. Although the healing depends upon immunity, pre-existing conditions such as hypertension, diabetes, cardiovascular diseases, or kidney diseases further enhances the severity of the pathogenesis of SARS-CoV-2 [17,19]. Different drugs are available in the market against SARS-CoV-2 but none has shown accurate results. None of the drugs has been approved by FDA against SARS-CoV-2.

Plants have been used as a medicine in the traditional Chinese and Ayurvedic systems [20]. Some of the herbal medicines have safety margins above those of reference drugs, which shows that they can be used against mild SARS-CoV-2 infection [21]. Plants in the form of herbal medicine or dietary components act as immunomodulators and can be a potent antiviral against SARS-CoV-2 infection [22].

Medicinal plants contain diverse secondary metabolites, therefore, they have been the source of drugs against viral, bacterial, and protozoal infection, including cancer [23,24]. The secondary metabolites present in the medicinal plants can interrupt viral proteins and enzymes by binding with them and preventing viral penetration and replication [25–28]. When consumed without knowing the appropriate dosage, herbal medicines may be toxic [29]. The genetically modified (GM) plants also pose serious health issues because the unnatural change in naturally occurring protein or the metabolic pathways results in toxins or allergens [30]. Therefore, the selection of medicinal plants is also an important aspect.

Vitamins play a major role in preventing established respiratory infection and intensive care settings. Vitamins enhance natural barriers because of their antioxidant and immunomodulatory effect and this could be beneficial against SARS-CoV-2 [31]. Mineral elements such as selenium and zinc have shown antiviral effects by enhancing the immune responses [32,33].

In this review article, we have tried to highlight the use of medicinal plants against different viral diseases including SARS-CoV-2, and also the possible factors (vitamins and minerals) that could be helpful against SARS-CoV-2.

2. Plants as a Source of Medicine against SARS-CoV-2

2.1. *Glycyrrhiza Glabra*

Glycyrrhiza glabra belongs to the family Fabaceae and is commonly known as licorice. Dried roots from the plant have a characteristic odor and sweet taste. Glycyrrhizin is the main component isolated from the roots. Glycyrrhizin inhibited 50% hepatitis C virus (HCV) in a dose-dependent manner at a concentration of $14 \pm 2 \mu\text{g}$ [34].

Glycyrrhizin also protects from the influenza A virus and caused a reduction in influenza-infected lung cells [35]. In addition to being effective against hepatitis and influenza virus, it has also shown its effect on SARS CoV [31]. Cinatal et al. [36] showed that glycyrrhizin effectively inhibited the SARS-CoV virus replication at an early stage. They were also of opinion that glycyrrhizin affected cellular signaling pathways such as protein kinase C, casein kinase II, and transcription factors such as protein 1 and nuclear factor B. Furthermore, they also concluded the upregulation of nitrous oxide that inhibits the virus.

Sinha et al. [37] through in silico approach showed that the replication process of SARS-CoV-2 was affected by the two components of licorice (glyasperin A and glycyrrhizic acid) They concluded that the ACE-2 receptor of the virus was disturbed by glycyrrhizic acid and the replication process was inhibited by glyasperin A (Table 1).

2.2. *Alnus Japonica*

Alnus japonica, also known as the East Asian alder tree, grows approximately up to 22 m. It is deciduous with a very fast growth rate. It belongs to the family Betulaceae, also known as the birch family, which includes six genera having nut-bearing deciduous trees and shrubs. The extract of leaves and bark of *Alnus japonica* have been used as food that boosts immunity against influenza [38]. Studies have shown that methanolic extract of *Alnus japonica* bark possesses strong antiviral activity against the H9N2 subtype avian influenza virus [39]. Further, the chromatographic separation revealed the presence of four lupine type triterpenes and one steroid [39].

Diarylheptanoids isolated from *Alnus japonica* showed inhibitory activity against papain-like protease (required for replication of SARS-CoV) [40]. Nine diarylheptanoids were isolated, namely, platyphyllenone, hirsutenone, hirsutanonol, oregonin, rubranol, rubranoside B, and rubranoside A. Furthermore, hirsutenone, hirsutanonol, oregonin, rubranol, rubranoside B, and rubranoside A showed dose-dependent inhibitory activity against the papain-like protease. They also showed that hirsutenone possessed the most potent inhibitory activity against papain-like protease. Furthermore, the analysis of Park et al. [40] showed that catechol and α,β -unsaturated carbonyl moiety were present in the molecule, which are the key requirements for SARS-CoV cysteine protease inhibition.

Furthermore, Kwon et al. [41] described that *Alnus japonica* extract is useful for prevention from viral diseases, such as influenza of humans and of other mammalian and avian species. They also said that the extract exhibits very low toxicity in normal cell conditions but has high antiviral activity. Lastly, the extract from *Alnus japonica* could be effectively used in foods and pharmaceutical industries against the influenza virus.

2.3. *Allium Sativum*(Garlic)

Allium sativum belongs to the Amaryllidaceae family. It is a perennial flowering plant that grows from a bulb and comprises a tall flowering stem that attains a height of upto 1 m. *Allium sativum* is commonly called garlic, which is also an ingredient in Indian food. A peculiar smell can be noticed from the bulb of garlic, which is due to the presence of sulfur compounds. In addition to possessing antibacterial activity, *Allium sativum* (garlic) also has antiviral properties. *Allium sativum* extract has an inhibitory effect on avian infectious bronchitis virus, which is a single-stranded RNA and belongs to coronaviruses. It has also shown its effect on other viruses including influenza A and B [42], cytomegalovirus [43], herpes simplex virus 1 [44], and herpes simplex virus-2 [45].

Molecular docking studies have revealed that garlic can inhibit SARS-CoV-2 [46]. Molecular docking has shown that 17 organosulfur compounds from garlic essential oil can effectively interact with the amino acid of angiotensin-converting enzyme (ACE-2), a receptor in the human body and main protease (PDB6LU7) of SARS-CoV-2. The highest efficacy was observed by allyl disulfide and allyl trisulfide. Furthermore, it was predicted that garlic essential oil or extract can be used as a source of antiviral against SARS-CoV-2 [46].

2.4. *Houttuynia Cordata*

Houttuynia cordata belongs to the family Saururaceae and is mostly confined to the moist habitat. It is an aromatic medicinal plant that has a creeping rootstock. Ethyl acetate extract of *Houttuynia cordata* is effective in inhibiting the infectivity of the dengue virus (DENV). Some workers have shown the inhibition of DENV-2 by ethyl acetate extract of *Houttuynia cordata* [47,48]. *Houttuynia cordata* extract also inhibited the avian infectious bronchitis virus [49]. Quercetin 3-rhamnoside from *Houttuynia cordata* showed anti-influenza (inf-A) activity and inhibited virus replication in the initial stages of infection [50]. Stem distillate from the *Houttuynia cordata* has shown inhibitory activity against herpes simplex virus-1, influenza virus, and human immunodeficiency virus-1 without any cytotoxicity [51]. The three major components from the distillate were methyl *n*-nonyl ketone, lauryl aldehyde, and capryl aldehyde.

Houttuynia cordata showed significant inhibition on SARS-CoV. The *Houttuynia cordata* (HC) extract successfully inhibited the SARS-CoV3C such as protease (3CLpro) and RNA-dependent RNA polymerase (RdRp) [52]. Furthermore, it was also observed that *Houttuynia cordata* extract was non-toxic to animal models at an oral administration dose of 16 g/kg. Through flow cytometric analysis, Lau et al. [52] showed that *Houttuynia cordata* extract in mice model significantly increases the CD4+ and CD8+ T cells with a significant increase in the secretion of IL-2 and IL-10 cytokine in mouse splenic lymphocytes.

2.5. *Lycoris Radiata*

Lycoris radiata, which is commonly known as red spider lily, hell flower, red magic lily, or sometimes called equinox flower, belongs to the family Amaryllidaceae. *Lycoris radiata* has shown its effect against H5N1 [53]. Lycorine the active component of *Lycoris radiata* successfully inhibited the influenza virus, which is responsible for avian influenza infection [54]. Proteomic analysis revealed that lycorine alters protein expression in avian influenza virus-infected cells and the treatment with lycorine also decreased the levels of nuclear pore complex protein 93(Nup93, E2RSV7), which is a part of nuclear-cytoplasmic transport [54]. Lycoricidine derivatives obtained from the bulb of *Lycoris radiata* have also shown the anti-hepatitis C virus activity [55]. Furthermore, it has also been observed that Lycoricidine derivatives possess inhibitory activity against the tobacco mosaic virus [56].

Ethanol extract of the stem cortex of the plant successfully inhibited the SARS-CoV. [57]. The active component that probably inhibited the SARS-CoV was lycorine (C₁₆H₁₇NO₄), which was analyzed by high-performance liquid chromatography

(HPLC). Although the mechanism of action of lycorine on the SARS-CoV is still unclear, it has shown promising results as an antiviral. Li et al. [57] also showed that commercially available lycorine inhibited the SARS-CoV.

2.6. *Tinospora Cordifolia*

Tinospora cordifolia, commonly called Guduchi or Giloy, belongs to the family Menispermaceae. The plant is an herbaceous vine that bears heart-shaped leaves. *Tinospora cordifolia* extract has shown an increase in IFN- α , IL-1, IL-2, and IL-4 levels in the peripheral blood mononuclear cells in the chickens infected with infectious bursal disease virus, which causes infectious bursal disease [58]. Further, the reduction in the mortality rate of chickens treated with *Tinospora cordifolia* extract was also observed when compared with uninfected chickens [58].

The stem extract of *Tinospora cordifolia* has antibacterial, antifungal, and antiviral properties. The stem extract of *Tinospora cordifolia* successfully inhibited the herpes simplex virus by 61.43% in the Vero cell line [59]. Kalikar et al. [60] showed that 60% of the patients who received *Tinospora cordifolia* extract and 20% on placebo showed a decrease in the incidence of various symptoms associated with HIV. However, they did not study all the parameters but hypothesized that *Tinospora cordifolia* extract could be used as an adjunct to HIV management. The in silico approach against SARS-CoV-2 was tested by Sagar and Kumar [61]. The key targets they considered for the docking were surface glycoprotein, receptor-binding domain, RNA-dependent RNA polymerase, and protease. The natural compounds from *Tinospora cordifolia* such as berberine, isocolumbin, magnoflorine, and tinocordiside showed high binding efficacy against all four key targets [61].

2.7. *Vitex Trifolia*

Vitex trifolia belongs to the family Verbenaceae. The leaves of the plants are compound and oppositely arranged with three linear leaflets ranges between 1–12 cm in length. The upper surface of the leaf is mostly green, whereas the lower surface is grayish.

Fruits of the plants contain essential oils, monoterpenes, diterpenes, beta-sitosterol [62–68]. The leaves and bark of the plant contain essential oils, flavones, and artemetin [65]. Furthermore, the essential oil of *Vitex trifolia* is used as an anti-inflammatory and against headache, cold, cough, liver disorders, and HIV [66,67]. Extract from the leaves of *vitex trifolia* inhibited TNF- α and IL-1 β production in human U937 macrophages [68]. The components that were isolated from leaf extract were artemetin, casticin, vitexilactone, and maslinic acid. Wee et al. [68] also suggested that artemetin could be the active compound that suppressed TNF- α and IL-1 β production.

Due to the high contents of the phenolic compounds such as phenolic acid, flavones, and flavonols, it was analyzed that methanolic extract contains antioxidant and anti-cancer properties [69]. *Vitex trifolia* has also been found to block the NK-kB pathways that reduce inflammatory cytokines; this is a similar pathway that is being used in respiratory distress in SARS-CoV [70,71].

Table 1. Plants and their activity against different viral diseases.

Plants	Family	Plant Part	References
<i>Glycyrrhiza glabra</i>	Fabaceae	Roots	Hepatitis C [34]
			Influenza-A [35]
			SARS-CoV [36]
			SARS-CoV-2 [37]
<i>Alnus japonica</i>	Betulaceae	Leaves and bark	Influenza [38]
			H9N2 Avian influenza virus [39]
			SARS CoV [40]
<i>Allium sativum</i>	Amaryllidaceae	Bulb	Influenza A and B [42]
			Cytomegalovirus [43]
			Herpes simplex virus 1 [44]
			Herpes simplex virus 2 [45]
<i>Houttuynia cordata</i>	Saururaceae	Leaves, roots	SARS CoV [46]
			DEN V-2[47,48]
			Avian infection bronchitis virus [49]
			Influenza-A [50]
<i>Lycoris radiata</i>	Amaryllidaceae	Bulb, stem cortex	Herpes simplex virus-1 [51]
			SARS CoV [52]
			H5N1 [53]
			Hepatitis C [55]
<i>Tinospora cordifolia</i>	Menispermaceae	Stem	Tobacco mosaic virus [56]
			SARS CoV [57]
			HSV-1[59]
			HIV [60]
<i>Vitex trifolia</i>	Verbenaceae	Leaves	SARS-CoV [61]
			HIV [66,67]
			SARS-CoV [70,71]

3. Vitamins and Minerals

Vitamins and minerals are an essential requirement of our body since they help in wound healing, enhancing the immune system, etc. They are also required for converting food into energy and play a major role in cellular damage. There are two types of vitamins, fat-soluble and water-soluble, and here we have discussed only those vitamins and minerals that could have a probable role against SARS-CoV (Table 2).

Vitamin A also called retinol is the fat-soluble vitamin that has β -carotene as its plant-derived precursor. Vitamin A is also called as an anti-infective vitamin since many of the defensive mechanism of the body depends upon the supply of this vitamin. It has already been reported that calves having low vitamin A content are more susceptible to the infection since they lose the effectiveness of the bovine coronavirus vaccine [72]. Bronchitis virus, which is a kind of coronavirus, was more prominent in the chickens that were fed with vitamin A deficient diet [73]

Vitamin B is a complex of different vitamins together designated as vitamin B complex because it comprises of different vitamins (B1 and B2 up to B-12). Each vitamin has its specific requirement, and its deficiency is related to different diseases. Elderly people are more prone to vitamin B2 deficiency [74]. Vitamin B2, along with UV light, effectively reduced the titer of MERS-CoV in human plasma products [75]. Vitamin B3 inhibited neutrophil infiltration into the lungs causing a strong anti-inflammatory response during the ventilator-associated lung injury but also led to hypoxemia [76]. Vitamin B-12 improves sustained viral response in patients with hepatitis C [77]. Narayan and Nair [78], through computational analysis using different software, also predicted that Vitamin B12

inhibited RNA-dependent RNA polymerase activity of an nsp-12 protein in SARS-CoV-2. nsp-12 protein is associated with RNA-dependent RNA polymerase activity and is responsible for viral replication.

Vitamin C has shown a significant lowering of pneumonia in lower respiratory tract infections during clinical trials [79]. Therefore, it is suggested that vitamin C might work against SARS-CoV-2. There are reports that suggest that vitamin C had increased the resistance of chicken embryo organ culture against avian coronavirus infection [80].

Vitamin D is a prohormone vitamin and is produced during exposure to sunlight, although smaller amounts are obtained from the food as well. It has many roles, including the enhancement of cellular immunity through the induction of antimicrobial peptides [81,82]. SARS-CoV-2 infection can be lowered by targeting an unbalanced Renin-angiotensin system (RAS) with Vitamin D supplements [83]. The current pandemic of SARS-CoV-2 has led to a call for the widespread use of vitamin D supplements [83–86]. Some reviews have suggested vitamin D loading doses of 200,000–300,000 IU in 50,000 IU capsules reduce the severity of COVID-19 [87].

Vitamin E, along with Vitamin D, deficiency has caused the bovine coronavirus in calves [88].

Zinc is required for the functioning and maintenance of immune cells. Zinc also increases interferon α (IFN α) production by leukocytes [89] and mediates its antiviral activity in cells infected with the rhinovirus [90]. In combination with pyrithione, zinc inhibits the RNA transcription in SARS-CoV and SARS-CoV RNA polymerase activity in RNA-dependent RNA polymerase. Selenium could also be another alternative to treat against SARS-CoV. The synergistic effect of selenium with ginseng stem-leaf saponins could induce an immune response to a bronchitis coronavirus vaccine in chicken [91].

Table 2. Vitamins and their role.

Vitamins	Role
Vitamin-A	Deficiency of Vit-A leads to enhancement of Bronchitis virus in chicken [73]
Vitamin B2	Effectively reduced titer of MERS-CoV in human plasma products [75]
Vitamin B3	Strong anti-inflammatory response during the ventilator-associated lung injury [76]
	Improves sustained viral response in patients with hepatitis C [77]
Vitamin B-12	Inhibits RNA Dependent RNA polymerase activity of an nsp-12 protein in SARS-CoV-2 [78]
	Lowering of pneumonia in lower respiratory tract infection [79].
Vitamin C	Increase the resistance of chicken embryo organ culture against avian coronavirus infection [80]
	Enhancement of cellular immunity through induction of antimicrobial peptides [81,82].
	Lowering of SARS-CoV-2 infection by targeting unbalanced RAS [83].
Vitamin E	Deficiency of Vit-E along with Vit-D caused the bovine coronavirus in calves [88]

4. Conclusions

From this review, we attempted to highlight natural medicines that could be used against SARS-CoV-2. Different companies and institutes have launched vaccines after getting approval from World Health Organization (WHO), whereas some vaccines are still under clinical trials. Different antivirals that have been previously used against SARS, MERS, and influenza have been evaluated alone or in combination, but still, no fruitful response has been achieved. Furthermore, it has been reported that the virus has a high rate of mutation, which is again a hurdle in the development of a vaccine [92].

This review is based on the treatments given in the case of SARS-CoV and MERS, which could also be effective against SARS-CoV-2 since SARS-CoV-2 is closely related to SARS-CoV and have 80% sequence identical [8]. Plants are a good source of natural medication and an alternative to antibiotic treatment because the excessive use of antibiotics is responsible for drug resistance. Secondly, the main advantage of using plants is

that they are economically efficient, have high scalability and safety because the plants can be cultivated in a very low amount, and they also do not support the growth of human pathogens [93]. Plants have produced a large range of antiviral lectins, including griffithsin [94,95], cyanovirin [96–99] and cyanovirin-N-fusion proteins [100], and also the transgenic rice lines that express griffithsin and cyanovirin-N in the seeds, with or without antibody 2G12 [101]. Medicinal plants may be a good source of antivirals, but the accurate dosage and plant parts that have medicinal properties, such as root, shoot, etc., should be known prior to the consumption; otherwise, the adverse effect could also exist. Although the exact mechanism of action of plants on the virus is still unknown, we are of opinion that healthy food helps in boosting the immune system, which further prevents disease including SARS-CoV-2. Therefore, a nutritious diet that includes different vitamins, minerals should be consumed regularly.

5. Future Perspectives

Plants could be a better alternative to modern medicines in the future. To validate the hypothesis of plants as a medicine further, extensive research should be carried out on different medicinal plants so that correct dosage and toxicity levels may be known prior to application.

Author Contributions: Conceptualization, S.G.A., M.A.A. (Mohammad Azam Ansari) and H.M.K.; methodology, S.G.A. and M.A.A. (Mohammad Azam Ansari); validation, M.A.A. (Mohammad A. Alzohairy), A.A., M.N.A., S.A. and S.R.; investigation, S.G.A., M.A.A. (Mohammad Azam Ansari), A.A., and S.A.; resources, writing—original draft preparation, S.G.A. and M.A.A. (Mohammad Azam Ansari); writing—review and editing, M.A.A. (Mohammad A. Alzohairy), A.A., M.N.A., S.A., S.R. and H.M.K.; All authors have read and agreed to the published version of the manuscript.

Funding: Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia, Grant number-Covid19-2020-002-IRMC.

Institutional Review Board Statement: Not Applicable.

Informed Consent Statement: Not Applicable.

Data Availability Statement: Not Applicable.

Acknowledgments: Syed Ghazanfar Ali would like to acknowledge Viral Research Diagnostic Laboratory (funded by DHR-ICMR-New Delhi) in Aligarh U.P India for giving an opportunity to work as a Research Scientist (Non-medical).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Gorbalenya, A.E.; Baker, S.C.; Baric, R.S.; de Groot, R.J.; Drosten, C.; Gulyaeva, A.A.; Haagmans, B.L.; Lauber, C.; Leontovich, A.M.; Neuman, B.W.; et al. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. *Nat. Microbiol.* **2020**, *5*, 536–544, doi:10.1038/s41564-020-0695-z.
2. Ansari, M.A.; Almatroudi, A.; Alzohairy, M.A.; AlYahya, S.; Alomary, M.N.; Al-Dossary, H.A.; Alghamdi, S. Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine—promising therapeutic strategy for SARS-CoV-2 treatment. *Expert Opin. Drug Deliv.* **2020**, *17*, 671–1674.
3. Chan, J.F.W.; Kok, K.H.; Zhu, Z.; Chu, H.; To, K.K.W.; Yuan, S.; Yuen, K.Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerg. Microbes Infect.* **2020**, *9*, 221–236.
4. Song, Z.; Xu, Y.; Bao, L.; Zhang, L.; Yu, P.; Qu, Y.; Zhu, H.; Zhao, W.; Han, Y.; Qin, C. From SARS to MERS, thrusting coronaviruses into the spotlight. *Viruses* **2019**, *11*, 59.
5. Zaki, A.M.; Van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N. Engl. J. Med.* **2012**, *367*, 1814–1820, doi:10.1056/NEJMoa1211721.
6. van Boheemen, S.; de Graaf, M.; Lauber, C.; Bestebroer, T.M.; Raj, V.S.; Zaki, A.M.; Osterhaus, A.D.M.E.; Haggmans, B.L.; Gorbalenya, A.E.; Snijder, E.J.; Fouchier, R.A.M. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. *MBio* **2012**, *3*, e00473-12.
7. Schoeman, D.; Fielding, B.C. Coronavirus envelope protein: Current knowledge. *Virology* **2019**, *16*, 69, doi:10.1186/s12985-019-1182-0.

8. Ansari, M.A.; Jamal, Q.M.S.; Rehman, S.; Almatroudi, A.; Alzohairy, M.A.; Alomary, M.N.; Tripathi, T.; Alharbi, A.H.; Adil, S.F.; Khan, M.; et al. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19. *Arab. J. Chem.* **2020**, *13*, 8069–8079.
9. Chan, J.F.-W.; Yuan, S.; Kok, K.-H.; To, K.K.-W.; Chu, H.; Yang, J.; Xing, F.; BNurs, J.L.; Yip, C. C.-Y.; Poon, R.W.-S.; et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. *Lancet* **2020**, *395*, 514–523.
10. Xu, X.; Chen, P.; Wang, J.; Feng, J.; Zhou, H.; Li, X.; Zhong, W.; Hao, P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Sci. China Life Sci.* **2020**, *63*, 457–460.
11. Zhao, Y.; Zhao, Z.; Wang, Y.; Zhou, Y.; Ma, Y.; Zuo, W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV. *Am. J. Respir. Crit. Care Med.* **2020**, *202*, 756–759.
12. Yin, Y.; Wunderink, R.G. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology* **2018**, *23*, 130–137.
13. Wan, Y.; Shang, J.; Graham, R.; Baric, R.S.; Li, F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *J. Virol.* **2020**, *94*, e00127–20, doi:10.1128/JVI.00127-20.
14. Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu. Rev. Virol.* **2016**, *3*, 237–261.
15. Song, W.; Gui, M.; Wang, X.; Xiang, Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. *PLoS Pathog.* **2018**, *14*, e1007236.
16. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* **2003**, *426*, 450–454.
17. Gralinski, L.E.; Menachery, V.D. Return of the coronavirus: 2019-nCoV. *Viruses* **2020**, *12*, 135, doi:10.3390/v12020135.
18. Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **2020**, *579*, 270–273.
19. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **2020**, *395*, 497–506.
20. Jaiswal, Y.; Liang, Z.; Zhao, Z. Botanical drugs in Ayurveda and traditional Chinese medicine. *J. Ethnopharmacol.* **2016**, *194*, 245–259.
21. Silveira, D.; Prieto-Garcia, J.M.; Boylan, F.; Estrada, O.; Fonseca-Bazzo, Y.M.; Jamal, C.M.; Magalhães, P.O.; Pereira, E.O.; Tomczyk, M.; Heinrich, M. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy? *Front. Pharmacol.* **2020**, *11*, 581840.
22. Panyod, S.; Ho, C.-T.; Sheen, L.-Y. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. *J. Trad. Complement. Med.* **2020**, *10*, 420–427.
23. Gurib-Fakim, A. Medicinal plants: Traditions of yesterday and drugs of tomorrow. *Mol. Asp. Med.* **2006**, *27*, 1–93.
24. Harvey, A.L. Natural products as a screening resource. *Curr. Opin. Chem. Biol.* **2007**, *11*, 480–484.
25. Li, T.; Peng, T. Traditional Chinese herbal medicine as a source of molecules with antiviral activity. *Antivir. Res.* **2013**, *97*, 1–9.
26. Arbab, A.H.; Parvez, M.K.; Al-Dosari, M.S.; Al-Rehaily, A.J. In vitro evaluation of novel antiviral activities of 60 medicinal plants extracts against hepatitis B virus. *Exp. Ther. Med.* **2017**, *14*, 626–634.
27. Akram, M.; Tahir, I.M.; Shah, S.M.A.; Mahmood, Z.; Altaf, A.; Ahmad, K.; Munir, N.; Daniyal, M.; Nasir, S.; Mehboob, H. Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review. *Phytother. Res.* **2018**, *32*, 811–822.
28. Dhama, K.; Karthik, K.; Khandia, R.; Munjal, A.; Tiwari, R.; Rana, R.; Khurana, S.K.; Ullah, S.; Khan, R.U.; Alagawany, M. et al. Medicinal and therapeutic potential of herbs and plant metabolites/extracts countering viral pathogens-current knowledge and future prospects. *Curr. Drug Metab.* **2018**, *19*, 236–263.
29. Fatima, N.; Nayeem, N. Toxic effects as a result of herbal medicine intake. In *Toxicology—New Aspects to This Scientific Conundrum*; Intech Open: London, UK, 2016; pp. 193–204.
30. Fagan, J.; Antoniou, M.; Robinson, C. *GMO Myths and Truths*; Earth Open Source: London, UK, 2014.
31. Jovic, T.H.; Ali, S.R.; Ibrahim, N.; Jessop, Z.M.; Tarassoli, S.P.; Dobbs, T.D.; Holford, P.; Thornton, C.A.; Whitaker, I.S. Could Vitamins Help in the Fight Against COVID-19? *Nutrients* **2020**, *12*, 2550.
32. Acevedo-Murillo, J.A.; Leon, M.L.G.; Firo-Reyes, V.; Santiago-Cordova, J.L.; Gonzalez-Rodriguez, A.P.; Wong-Chew, R.M. Zinc supplementation promotes a Th1 response and improves clinical symptoms in fewer hours in children with pneumonia younger than 5 Years old. A randomized controlled clinical trial. *Front. Pediatrics* **2019**, *7*, 431.
33. Rayman, M.P. Selenium and human health. *Lancet* **2012**, *379*, 1256–1268.
34. Ashfaq, U.A.; Masoud, M.S.; Nawaz, Z.; Riazuddin, S. Glycyrrhizin as antiviral agent against Hepatitis C Virus. *J. Transl. Med.* **2011**, *9*, 112.
35. Wolkerstorfer, A.; Kurz, H.; Bachhofner, N.; Szolar, O.H. Glycyrrhizin inhibits influenza A virus uptake into the cell. *Antivir. Res.* **2009**, *83*, 171–178.
36. Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. *Lancet* **2003**, *361*, 2045–2046.
37. Sinha, S.K.; Prasad, S.K.; Islam, M.A.; Gaurav, S.S.; Patil, R.B.; Al-Faris, N.A.; Aldayel, T.S.; AlKehayez, N.M.; Wabaidur, S.M.; Shakya, A. Identification of bioactive compounds from *Glycyrrhiza glabra* as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: A pharmacoinformatics study. *J. Biomol. Struct. Dyn.* **2020**, 1–15, doi:10.1080/07391102.2020.177913.

38. Ra, J.C.; Kwon, H.J.; Kim, B.G.; You, S.H. Anti-Influenza Viral Composition Containing Bark or Stem Extract of *Alnus japonica*. US Patent US 2010/0285160 A1 11 November 2010.
39. Tung, N.H.; Kwon, H.J.; Kim, J.H.; Ra, J.C.; Kim, J.A.; Kim, Y.H. An anti-influenza component of the bark of *Alnus japonica*. *Arch. Pharm. Res.* **2010**, *33*, 363–367.
40. Park, J.Y.; Jeong, H.J.; Kim, J.H.; Kim, Y.M.; Park, S.J.; Kim, D.; Park, K.H.; Lee, W.S.; Ryu, Y.B. Diarylheptanoids from *Alnus japonica* inhibit papain-like protease of severe acute respiratory syndrome coronavirus. *Biol. Pharm. Bull.* **2012**, *35*, 2036–2042.
41. Kwon, J.H.; Cho, S.H.; Kim, S.J.; Ahn, Y.J.; Ra, J.C. Antiviral Composition Comprising *Alnus Japonica* Extracts. US Patent US 2010/0189827 A1, 29 July 2010.
42. Fenwick, G.R.; Hanley, A.B. *Allium* species poisoning. *Vet. Rec.* **1985**, *116*, 28.
43. Meng, Y.; Lu, D.; Guo, N.; Zhang, L.; Zhou, G. Anti-HCMV effect of garlic components. *Virol. Sin.* **1993**, *8*, 147–150.
44. Tsai, Y.; Cole, L.L.; Davis, L.E.; Lockwood, S.J.; Simmons, V.; Wild, G.C. Antiviral properties of garlic: In vitro effects on influenza B, herpes simplex and coxsackie viruses. *Planta Med.* **1985**, *5*, 460–461.
45. Weber, N.D.; Andersen, D.O.; North, J.A.; Murray, B.K.; Lawson, L.D.; Hughes, B.G. In vitro virucidal effects of *Allium sativum* (garlic) extract and compounds. *Planta Med.* **1992**, *58*, 417–423.
46. Thuy, B.T.P.; My, T.T.A.; Hai, N.T.T.; Hieu, L.T.; Hoa, T.T.; Loan, H.T.T.P.; Triet, N.T.; Anh, T.T.V.; Quy, P.T.; Tat, P.V. et al. Investigation into SARS-CoV-2 Resistance of Compounds in Garlic Essential Oil. *ACS Omega* **2020**, *5*, 8312–8320, doi:10.1021/acsomega.0c00772.
47. Chiow, K.H.; Phoon, M.C.; Putti, T.; Tan, B.K.; Chow, V.T. Evaluation of Antiviral Activities of *Houttuynia Cordata* Thunb. Extract, Quercetin, Quercetrin and Cinanserin on Murine Coronavirus and Dengue Virus Infection. *Asian Pac. J. Trop. Med.* **2016**, *9*, 1–7.
48. Xie, M.L.; Phoon, M.C.; Dong, S.X.; Tan, B.K.H.; Chow, V.T. *Houttuynia cordata* extracts and constituents inhibit the infectivity of dengue virus type 2 in vitro. *Int. J. Integr. Biol.* **2013**, *14*, 78–85.
49. Yin, J.; Li, G.; Li, J.; Yang, Q.; Ren, X. In vitro and in vivo effects of *Houttuynia cordata* on infectious bronchitis virus. *Avian Pathol.* **2011**, *40*, 491–498.
50. Choi, H.J.; Song, J.H.; Park, K.S.; Kwon, D.H. Inhibitory effects of quercetin 3-rhamnoside on influenza A virus replication. *Eur. J. Pharm. Sci.* **2009**, *37*, 329–333.
51. Hayashi, K.; Kamiya, M.; Hayashi, T. Virucidal effects of the steam distillate from *Houttuynia cordata* and its components on Hsv-1, Influenza-Virus, and HIV. *Planta Med.* **1995**, *61*, 237–241.
52. Lau, K.M.; Lee, K.M.; Koon, C.M.; Cheung, C.S.; Lau, C.P.; Ho, H.M.; Lee, M. Y-H.; Au, S.W-N.; Cheng, C. H-K.; Lau, C.B-S. et al. Immunomodulatory and anti-SARS activities of *Houttuynia cordata*. *J. Ethnopharmacol.* **2008**, *118*, 79–85.
53. He, J.; Qi, W.B.; Wang, L.; Tian, J.; Jiao, P.R.; Liu, G.Q.; Ye, W-C.; Liao, M. Amaryllidaceae alkaloids inhibit nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic avian influenza virus H5N1. *Influenza Other Respir. Viruses* **2012**, *7*, 922–931.
54. Yang, L.; Zhang, J.H.; Zhang, X.L.; Lao, G.J.; Su, G.M.; Wang, L.; Li, Y. L.; Ye, W. C.; He, J. Tandem mass tag-based quantitative proteomic analysis of lycorine treatment in highly pathogenic avian influenza H5N1 virus infection. *Peer J.* **2019**, *7*, e7697.
55. Chen, D.Z.; Jiang, J.D.; Zhang, K.Q.; He, H.P.; Di, Y.T.; Zhang, Y.; Cai, J-Y.; Wang, L.; Li, S-L. Yi, P. et al. Evaluation of anti-HCV activity and SAR study of (+)-lycoridine through targeting of host heat-stress cognate 70 (Hsc70). *Bioorg. Med. Chem. Lett.* **2013**, *23*, 2679–2682.
56. Yang, D.Q.; Chen, Z.R.; Chen, D.Z.; Hao, X.J.; Li, S.L. Anti-TMV Effects of Amaryllidaceae Alkaloids Isolated from the Bulbs of *Lycoris radiata* and Lycoridine Derivatives. *Nat. Prod. Bioprospect.* **2018**, *8*, 189–197.
57. Li, S.Y.; Chen, C.; Zhang, H.Q.; Guo, H.Y.; Wang, H.; Wang, L. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. *Antivir. Res.* **2005**, *67*, 18–23.
58. Sachan, S.; Dhama, K.; Latheef, S.K.; Samad, H.A.; Mariappan, A.K.; Munuswamy, P.; Singh, R.; Singh, K.P.; Malik, Y.S.; Singh, R.K. Immunomodulatory Potential of *Tinosporacordifolia* and CpG ODN (TLR21 Agonist) against the Very Virulent, Infectious Bursal Disease Virus in SPF Chicks. *Vaccines (Basel)* **2019**, *7*, 106.
59. Pruthvish, R. and Gopinatha, S.M. Antiviral prospective of *Tinospora cordifolia* on HSV-1. *Int. J. Curr. Microbiol. Appl. Sci.* **2018**, *7*, 3617–3624.
60. Kalikar, M.V.; Thawani, V.R.; Varadpande, U.K.; Sontakke, S.D.; Singh, R.P.; Khiyani, R.K. Immunomodulatory effect of *Tinospora cordifolia* extract in human immuno-deficiency virus positive patients. *Indian J. Pharmacol.* **2008**, *40*, 107–110.
61. Sagar, V.; Kumar, A.H.S. Efficacy of natural compounds from *Tinospora cordifolia* against SARS-CoV-2 protease, surface glycoprotein and RNA polymerase. *BEMS Rep.* **2020**, *6*, 6–8.
62. Cousins, M.M.; Briggs, J.; Gresham, C.; Whetstone, J. Beach Vitex (*Vitex rotundifolia*) an invasive coastal species. *Invasive Plant Sci. Manag. (Weed Sci. Soc. Am.)* **1991**, *6*, 101–103.
63. Zeng, X.; Fang, Z.; Wu, Y.; Zhang, H. Chemical constituents of the fruits of *Vitex trifolia* L. *Zhongguo Zhong Yao Za Zhi* **1996**, *21*, 167–168.
64. Ono, M.; Sawamura, H.; Ito, Y.; Mizuki, K.; Nohara, T. Diterpenoids from the fruits of *Vitex trifolia*. *Phytochemistry* **2000**, *55*, 873–877.
65. Chan, E.W.C.; Baba, S.; Chan, H.T.; Kainumaz, M.; Tangah, J. Medicinal plants of sandy shores a short review on *V trifolia* L. and *Iomoea pes caprae*. *Indian J. Nat. Prod. Resour.* **2016**, *7*, 107–115.

66. Devi, W.R.; Singh, C.B. Chemical composition, anti-dermatophytic activity, antioxidant and total phenolic content within the leaves essential oil of *Vitex trifolia*. *Int. J. Phytocosmetics Nat. Ingrid.* **2014**, *1*, 5–10.
67. Suksamrarn, A.; Werawattanamet, K.; Brophy, J.J. Variation of essential oil constituents in *Vitex trifolia* species. *FlavourFragr. J.* **1991**, *6*, 97–99.
68. Wee, H.N.; Neo, S.Y.; Singh, D.; Yew, H.C.; Qiu, Z.Y.; Tsai, X.R.C.; How, S.Y.; Yip, K-Y.C.; Tan, C-H.; Koh, H-L. Effects of *Vitex trifolia* L. Leaf Extracts and Phytoconstituents on Cytokine Production in Human U937 Macrophages. *BMC Complement. Med. Ther.* **2020**, *20*, 91.
69. Yao, J.L.; Fang, S.M.; Liu, R.; Oppong, MB.; Liu, E.W.; Fan, G.W.; Zhang, H. A Review on the Terpenes from Genus *Vitex*. *Molecules* **2016**, *21*, 1179.
70. Alam, G.; Wahyuono, S.; Ganjar, I.G.; Hakim, L.; Timmerman, H.; Verpoorte, R. Tracheospasmodic activity of viteosin-A and vitexicarpin isolated from *Vitex trifolia*. *Planta Med.* **2002**, *68*, 1047–1049.
71. Srivastava, R.A.K.; Mistry, S.; Sharma, S. A novel anti-inflammatory natural product from *Sphaeranthus indicus* inhibits expression of VCAM1 and ICAM1, and slows atherosclerosis progression independent of lipid changes. *Nutr. Metab.* **2015**, *12*, 20.
72. Jee, J.; Hoet, A.E.; Azevedo, M.P.; Vlasova, A.N.; Loerch, S.C.; Pickworth, C.L.; Hanson, J.; Saif, L.J. Effects of dietary vitamin A content on antibody responses of feedlot calves inoculated intramuscularly with an inactivated bovine coronavirus vaccine. *Am. J. Vet. Res.* **2013**, *74*, 1353–1362.
73. West, C.E.; Sijtsma, S.R.; Kouwenhoven, B.; Rombout, J.H.; van der Zijpp, A.J. Epithelia-damaging virus infections affect vitamin A status in chickens. *J. Nutr.* **1992**, *122*, 333–339.
74. Powers, H.J. Riboflavin (vitamin B-2) and health. *Am. J. Clin. Nutr.* **2003**, *77*, 1352–1360.
75. Keil, S.D.; Bowen, R.; Marschner, S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. *Transfusion* **2016**, *56*, 2948–2952.
76. Jones, H.D.; Yoo, J.; Crother, T.R.; Kyme, P.; Shlomo, A.B.; Khalafi, R.; Tseng, C.W.; Parks, W.C.; Arditi, M.; Liu, G. Y.; Shimada, K. Nicotinamide exacerbates hypoxemia in ventilator-induced lung injury independent of neutrophil infiltration. *PLoS ONE* **2015**, *10*, e0123460, doi:10.1371/journal.pone.0123460.
77. Rocco, A.; Compare, D.; Coccoli, P.; Esposito, C.; Spirito, A.D.; Barbato, A.; Strazzullo, P.; Nardone, G. Vitamin B12 Supplementation Improves Rates of Sustained Viral Response in Patients Chronically Infected With Hepatitis C Virus. *Hepatology* **2013**, *62*, 766–773.
78. Narayanan, N.; Nair, D.T. Vitamin B12 May Inhibit RNA-Dependent-RNA Polymerase Activity of nsp12 from the SARS-CoV-2 Virus. *IUBMB Life* **2020**, *72*, 2112–2120.
79. Hemila, H. Vitamin C intake and susceptibility to pneumonia. *Pediatr. Infect. Dis.J.* **1997**, *16*, 836–837.
80. Atherton, J.G.; Kratzing, C.C.; Fisher, A. The effect of ascorbic acid on infection chick-embryo ciliated tracheal organ cultures by coronavirus. *Arch. Virol.* **1978**, *56*, 195–199.
81. Liu, P.T.; Stenger, S.; Li, H.; Wenzel, L.; Tan, B.H.; Krutzik, S.R.; Ochoa, M.T.; Schaubert, J.; Wu, K.; Meinken, C.; et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* **2006**, *311*, 1770–1773.
82. Adams, J.S.; Ren, S.; Liu, P.T.; Chun, R.F.; Lagishetty, V.; Gombart, A.F.; Borregaard, N.; Modlin, R.L.; Hewison, M. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. *J. Immunol.* **2009**, *182*, 4289–4295.
83. Garami, A.R. Preventing a covid-19 pandemic—Is there a magic bullet to save COVID-19 patients? We can give it a try! *BMJ* **2020**, *368*, m810.
84. Grant, W.B.; Lahore, H.; McDonnell, S.L.; Baggerly, C.A.; French, C.B.; Aliano, J.L.; Bhattoa, H.P. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients* **2020**, *12*, 988.
85. McCartney, D.M.; Byrne, D.G. Optimisation of vitamin D status for enhanced Immuno-protection against Covid-19. *Ir. Med. J.* **2020**, *113*, 58.
86. Schwalfenberg, G.K. Preventing a COVID-19 pandemic. Covid 19, Vitamin D deficiency, Smoking, Age and Lack of Masks Equals the Perfect Storm: Rapid response. *BMJ* **2020**, *368*, m810.
87. Wimalawansa, S.J. Global epidemic of coronavirus–COVID-19: What we can do to minimize risks. *Eur. J. Biomed. Pharm. Sci.* **2020**, *7*, 432–438.
88. Nonnecke, B.J.; McGill, J.L.; Ridpath, J.F.; Sacco, R.E.; Lippolis, J.D.; Reinhardt, T.A. Acute phase response elicited by experimental bovine diarrhoea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete pre-ruminant calves. *J. Dairy Sci.* **2014**, *97*, 5566–5579.
89. Cakman, I.; Kirchner, H.; Rink, L. Zinc supplementation reconstitutes the production of interferon- α by leukocytes from elderly persons. *J. Interferon Cytokine Res.* **1997**, *17*, 469–472.
90. Berg, K.; Bolt, G.; Andersen, H.; Owen, T.C. Zinc potentiates the antiviral action of human IFN- α tenfold. *J. Interferon Cytokine Res.* **2001**, *21*, 471–474.
91. Ma, X.; Bi, S.; Wang, Y.; Chi, X.; Hu, S. Combined adjuvant effect of ginseng stem-leaf saponins and selenium on immune responses to a live bivalent vaccine of Newcastle disease virus and infectious bronchitis virus in chickens. *Poult. Sci.* **2019**, *98*, 3548–3556.
92. Vellingiri, B.; Jayaramayya, K.; Iyer, M.; Narayanasamy, A.; Govindasamy, V.; Giridharan, B.; Ganesan S.; Venugopal, A.; Venkatesan, D.; Ganesan, H. et al. Covid-19: A promising cure for the global panic. *Sci. Total Environ.* **2020**, *725*, 138277.
93. Ma, J.K.; Drake, P.M.; Chritou, P. The production of recombinant pharmaceutical proteins in plants. *Nat. Rev. Genet.* **2003**, *4*, 794–805.

94. Keefe, B.R.O.; Vojdani, F.; Buffa, V.; Shattock, R.J.; Montefiori, D.C.; Bakke, J.; Mirsalis, J.; d'Andrea, A-L.; Hume, S.D.; Bratcher, B.; et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 6099–6104.
95. Vamvaka, E.; Arcalis, E.; Ramessar, K.; Evans, A.; Keefe, B.R.O.; Shattock, R.J.; Medina, V.; Stoger, E.; Christou, P.; Capell, T. Rice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV. *Plant Biotechnol. J.* **2016**, *14*, 1427–1437.
96. Sexton, A.; Drake, P.M.; Mahmood, N.; Harman, S.J.; Shattock, R.; Ma, J.K.C. Transgenic plant production of cyanovirin-N, an HIV microbicide. *FASEB J.* **2006**, *20*, 356–358.
97. Drake, P.M.W.; Madeira, L.D.M.; Szeto, T.H.; Ma, J.K.C. Transformation of *Althaea officinalis* L. by *Agrobacterium rhizogenes* for the production of transgenic roots expressing the anti-HIV microbicide cyanovirin-N. *Transgenic Res.* **2013**, *22*, 1225–1229.
98. Keefe, B.R.O.; Murad, A.M.; Vianna, G.R.; Ramessar, K.; Saucedo, C.J.; Wilson, J.; Buckheit, K.W.; da-Cunha, N.B.; Araujo, A.C.G.; Lacorte, C.C et al. Engineering soya bean seeds as a scalable platform to produce cyanovirin-N, a non-ARV microbicide against HIV. *Plant Biotechnol. J.* **2015**, *13*, 884–892.
99. Vamvaka, E.; Evans, A.; Ramessar, K.; Krumpe, L.R.H.; Shattock, R.J.; Keefe, B.R.O.; Christou, P.; Capell, T. Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro. *Plant Cell Rep.* **2016**, *35*, 1309–1319.
100. Sexton, A.; Harman, S.; Shattock, R.J.; Ma, J.K.C. Design, expression, and characterization of a multivalent, combination HIV microbicide. *FASEB J.* **2009**, *23*, 3590–3600.
101. Vamvaka, E.; Farre, G.; Molinos-Albert, L.M.; Evans, A.; Canela-Xandri, A.; Twyman, R.M.; Carrillo, J.; Ordonez, R.A.; Shattock, R.J.; O'Keefe, B.R.; et al. Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E7854–E7862.